134 related articles for article (PubMed ID: 2415118)
21. Dihydro- and tetrahydroisoquinolines as inhibitors of cyclic nucleotide phosphodiesterases from dog heart. Structure-activity relationships.
Van Inwegen RG; Salaman P; St Georgiev V; Weinryb I
Biochem Pharmacol; 1979 Apr; 28(8):1307-12. PubMed ID: 87199
[No Abstract] [Full Text] [Related]
22. Action of trapidil on the heart contractility: relationship to the cyclic nucleotide metabolism.
Bartel S; Reese D; Krause EG
Biomed Biochim Acta; 1987; 46(8-9):S472-6. PubMed ID: 2829868
[TBL] [Abstract][Full Text] [Related]
23. The effects of alkylated xanthines on cyclic AMP accumulation in dog thyroid slices exposed to carbamylcholine.
Miot F; Erneux C; Wells JN; Dumont JE
Mol Pharmacol; 1984 Mar; 25(2):261-6. PubMed ID: 6321949
[TBL] [Abstract][Full Text] [Related]
24. [The effectiveness of trapidil and some derivatives on heart function under in vitro and in vivo conditions].
Mentz P; Pawelski KE; Orlova ZR; Giessler C; Mest HJ
Pharmazie; 1987 Jun; 42(6):403-6. PubMed ID: 3313438
[TBL] [Abstract][Full Text] [Related]
25. [Inhibition of platelet aggregation and cyclic nucleotide phosphodiesterase (specifically cyclAMP) by 3-hydroxypyridine derivatives].
Kagan VE; Polianskiĭ NB; Muranov KO; Shvedova AA; Smirnov LD
Biull Eksp Biol Med; 1984 Apr; 97(4):416-8. PubMed ID: 6202339
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of cyclic AMP phosphodiesterase activity and myocardial contractility: effects of cilostamide, a novel PDE inhibitor, and methylsiobutylxanthine on rabbit and canine ventricular muscle.
Endoh M; Satoh K; Yamashita S
Eur J Pharmacol; 1980 Aug; 66(1):43-52. PubMed ID: 6157546
[No Abstract] [Full Text] [Related]
27. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
Ilien B; Ruckstuhl M; Landry Y
J Pharmacol; 1982; 13(2):307-16. PubMed ID: 6285085
[TBL] [Abstract][Full Text] [Related]
28. Effects of DN-9693, a selective inhibitor of cyclic AMP phosphodiesterase, in isolated and perfused canine large coronary arteries.
Nakane T; Chiba S
Jpn J Pharmacol; 1988 Dec; 48(4):507-9. PubMed ID: 2468805
[TBL] [Abstract][Full Text] [Related]
29. Silymarin: potent inhibitor of cyclic AMP phosphodiesterase.
Koch HP; Bachner J; Löffler E
Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):409-13. PubMed ID: 3001454
[TBL] [Abstract][Full Text] [Related]
30. [Effect of antioxidants of the 3-hydroxypyridine class on cyclic 3', 5'-adenosine monophosphate phosphodiesterase activity].
Smirnov LD; Malykhina LS; Lazarevich VG; Fedorov NA
Biull Eksp Biol Med; 1983 Sep; 96(9):40-2. PubMed ID: 6311309
[TBL] [Abstract][Full Text] [Related]
31. Activation of human lymphocyte high affinity cyclic AMP phosphodiesterase by culture with 1-methyl-3-isobutylxanthine.
Thompson WJ; Ross CP; Hersh EM; Epstein PM; Strada SJ
J Cyclic Nucleotide Res; 1980; 6(1):25-36. PubMed ID: 6155390
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of lipolytic action of a new alpha-2 adrenergic antagonist of the piperazinopyrimidine family: RP 55462.
Saulnier-Blache JS; Taouis M; Dauzats M; Uzan A; Berlan M; Lafontan M
J Pharmacol Exp Ther; 1989 Dec; 251(3):1193-8. PubMed ID: 2481031
[TBL] [Abstract][Full Text] [Related]
33. Analysis of relaxant effects of trapidil in isolated dog coronary artery.
Sakanashi M; Yoshikawa Y; Kondoh G; Fukai R; Hirata A; Higuchi M
Arzneimittelforschung; 1980; 30(11):1871-4. PubMed ID: 7192995
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
36. 2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity.
Benjamin CW; Lin AH; Morris J; Wishka DG; Gorman RR
J Pharmacol Exp Ther; 1993 Apr; 265(1):457-62. PubMed ID: 7682615
[TBL] [Abstract][Full Text] [Related]
37. [The effectiveness of trapidil and trapidil derivatives on drug-induced heart arrhythmias in the rat and guinea pig].
Riedel A; Schneider S; Mest HJ
Arzneimittelforschung; 1987 Aug; 37(8):923-6. PubMed ID: 3675688
[TBL] [Abstract][Full Text] [Related]
38. Effects of trapidil-derivatives on calcium channel currents in isolated ventricular cells from mice.
Markwardt F; Nilius B
Naunyn Schmiedebergs Arch Pharmacol; 1988 Apr; 337(4):454-8. PubMed ID: 2457174
[TBL] [Abstract][Full Text] [Related]
39. Tissue and species specificity of cardiac cAMP-phosphodiesterase inhibitors.
Pang DC
Adv Second Messenger Phosphoprotein Res; 1992; 25():307-20. PubMed ID: 1313264
[No Abstract] [Full Text] [Related]
40. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
